ESTRACE® (Estradiol) WARNINGS for Women in Menopause – Carla’s Story

by | Sep 26, 2015


If you are taking ESTRACE®, or any other form of Estradiol, including Hormone Pellet Implants that include Estradiol, you need to read the WARNING label very carefully. Synthetic Hormone Replacement with any form of Estradiol or Estrone can cause serious life threatening risks, including heart attacks, strokes, blood clots, breast cancer, uterine cancer and dementia. Menopausal hormone imbalances now frequently begin when a woman is in her 40’s. Peri-Menopause and Menopausal symptoms are much more than a mere annoyance. Hormonal Imbalance can lead to Cancer, Heart Disease and Osteoporosis,  but synthetic hormones, Birth Control Pills, Hysterectomy or Ablation treatments do not correct the Hormone Imbalance AND can cause more harm than good.

WARNING

A green chalkboard with the message 'I LOVE YOU' written in white chalk.
 
 

This is the story of my patient Carla

When Carla first came to see me she was 51. She had had a Hysterectomy (removed her uterus but not her ovaries) at age 49 because she had developed heavy uterine bleeding every 2 weeks, which she described as gushing.
After her hysterectomy, her doctor put her on Estrace® but that seemed to only make her more irritable and gain more weight. She put on 30 lbs in less than 2 years. She didn’t want to stay on Estrace® because she had heard it was dangerous and her mother had died of breast cancer 8 years prior, so she finally decided to quit taking it and her hot flashes came back.
Carla had a long history of PMS symptoms, including moodiness, irritability, breast tenderness, as well as a major craving for sugar and salt. These are symptoms of high  Estradiol and Estrone (the concentrated, cancer causing estrogens) and low Estriol and Progesterone (the natural anti-cancer hormones the body makes to counter the other two). Her menses had been regular until age 45, when it started getting shorter and shorter and heavier and heavier
By the time Carla came to see me she was suffering from 2-3 hot flashes per day and 2-3 times every night; she has absolutely ZERO sex drive; she had vaginal dryness and pain when she and her husband have intercourse and she felt “edgy, irritable, anxious and scattered or in a fog all the time.”
Carla also described suffering from hypoglycemia, which caused headaches and feeling week if she missed meals or ate too much sugar or didn’t eat enough fiber or didn’t eat every 3-4 hours.
When I see a new patient, I look at the whole picture of health and review the symptoms of every system of the body to gather all the interactive clues I can to figure out all the hormone imbalances involved and how they inter-relate. I have come to recognize Menopause as a Multiple Hormone Deficiency Syndrome.
 

Carla’s Symptoms:  Hormone Deficiency

1)   Hot Flashes: night sweats, sleeplessness:  Estriol Deficiency
2)   Brain Fog, Memory Loss:  Estriol, Pregnenolone Deficiency
3)   Anxiety, Moodiness, Irritability:  Progesterone Deficiency

4)   Weight Gain in Abdomen:  DHEA, Testosterone Deficiency

5)   Thinning skin, bones:  Estriol, Growth Hormone Deficiency
6)   Sagging Skin, Fatty arms:  Growth Hormone Deficiency
7)   Low Sex Drive:  Testosterone Deficiency
8)   Fatigue, Can’t lose weight: Thyroid Deficiency
9)   Hypoglycemia, Light headedness:  Adrenal Cortisol Deficiency
 

What is causing more women to experience Menopause sooner?

A green chalkboard with the message 'I LOVE YOU' written in white chalk.

 

What is the Conventional Treatment for Menopause?

  • Ablation
  • Hysterectomy
  • Birth Control Pills
  • Premarin
  • Estrace® or other Estradiol containing Drugs
  • Estradiol/Testosterone Pellet Implants

 

What Hormones do you need to Test and Supplement?

You should be testing all 12 of the hormones listed on Carla’s Lab Results below. These are the hormones I always recommend for all my patients in Peri-Menopause or Menopause. They are all inter-related and must be balanced in order for you to feel great and prevent Cancer, Heart Disease, Osteoporosis, Dementia, Brain Fog, Moodiness, Fatigue, waning sex drive, vaginal atrophy, thinning skin, fattening weight gain and the aches and pains of Menopause.
You will see in the Chart below that Carla’s Cancer Causing Estrogens were very high because she had been taking Estrace® and because her protective Estriol and Progesterone were low. Within only 3 months, Carla was able to restore the proper balance by following my simple, safe and effective daily routine of taking Sub-lingual (under the tongue hormones). She felt fantastic and reduced her risk of disease significantly.
 

Carla’s Lab Results

A green chalkboard with the message 'I LOVE YOU' written in white chalk.

What is the best way to take Bio-Identical Hormones?

Sublingual Powder taken under the tongue is the best choice for both the short and the long term.

  • High Absorption (90%+)
  • Fast acting; goes directly into bloodstream
  • Consistent dose: No excessive build-up; easy to change;
  • No surgery: No Cancer Causing Chemicals

 

How is Carla doing now after Bio-Identical Hormone Therapy?

Within 2 weeks Carla’s hot flashes much better and within 6 weeks they were completely gone. She said she now has lots of energy, no more “brain fog,” feels less irritable, less scattered and more clear and sleeping better than she had in years.
At Carla’s 3 month follow-up, Carla reported feeling “awesome” for the first time in a very long time. Absolutely no more hot flashes or night sweats, her mood had mellowed out, her energy was back (in fact, she no longer needed her daily 1-1/2 cups of coffee – “Don’t need it at all,” she told me), she was sleeping really great, she had no more bloating and no more light headedness.
Carla was excited to find that she had lost 10 lbs on my “Vital Lifetime Diet” She said she loved our Vega Protein shakes and health menu plan because it made her feel satisfied and she wasn’t hungry at all. She said she loved getting back into exercising 30 minutes 4-5 days per week because she felt it really boosted her metabolism and her mood.
And, last but not least,Carla reported that her fingernails and hair were growing healthier and faster than ever before. She absolutely love the changes in herself. She felt like she had remade herself all over again to be the healthiest she had been in years and never wants to go back.
 
For more information about Dr. Hansen’s Bio-Identical Hormone Therapy, click here
 

Ivermectin + Mebendazole taken together produce remarkably Positive Clinical Cancer Benefits in 84.4% of Patients.

The largest real-world human analysis to date evaluating ivermectin and mebendazole in cancer patients has just been published—and the results represent one of the most compelling clinical signals ever documented for repurposed anti-parasitic therapies in oncology.

This groundbreaking analysis was made possible through a unique collaboration between The Wellness Company, the McCullough Foundation, and the Chairman of the President’s Cancer Panel (Dr. Harvey Risch)—uniting real-world clinical data, frontline medical experience, and high-level epidemiologic expertise to deliver urgently needed insights in oncology.

This was a real-world prospective clinical program evaluation of 197 cancer patients, with 122 completing a follow-up survey at about six months (61.9% response rate).

Cancer patients were prescribed compounded ivermectin–mebendazole, with each capsule containing 25 mg ivermectin and 250 mg mebendazole—most commonly taken at 1–2 capsules per day.

The cohort represented a clinically relevant population, including a wide variety cancer types, with 37.1% of patients reporting actively progressing disease at baseline and many having already undergone chemotherapy, radiation, and surgery.

At six months, 84.4% of cancer patients reported clinical benefit (Clinical Benefit Ratio: 84.4% [95% CI: 77.0–89.8%]):

✅ 32.8% reported NO evidence of cancer (95% CI: 25.1–41.5%)
✅ 15.6% reported tumor regression (95% CI: 10.2–23.0%)
✅ 36.1% reported stable disease (95% CI: 28.1–44.9%)

Treatment adherence was high, with 86.9% completing the full protocol and 66.4% remaining on therapy at six months.

The regimen was well tolerated, with 25.4% reporting side effects, primarily mild and gastrointestinal, and over 93% continuing treatment despite these events.

Patients were treated in real-world conditions alongside concurrent therapies, including chemotherapy (27.9%), radiation (21.3%), surgery (19.7%), supplements (49.2%), and dietary modification (37.7%), supporting use as an adjunctive approach.

Together, these findings represent a large, internally consistent real-world clinical signal that supports URGENT further investigation of ivermectin and mebendazole as low-toxicity, adjunctive cancer therapies.

Given the strength of the signal observed here, advancing this line of investigation is no longer optional—it is necessary.

This is NOT the end. We will continue advancing this work with larger datasets to further define and validate the role of anti-parasitics in cancer outcomes.

The manuscript is now available as a preprint on the Zenodo research repository, operated by the European Organization for Nuclear Research, while undergoing peer review at leading oncology journals: “Real-World Clinical Outcomes of Ivermectin and Mebendazole in Cancer Patients: Results from a Prospective Observational Cohort.”

Bar chart showing distribution of common cancer types with breast cancer most prevalent.
Infographic on disease status and median duration since diagnosis.

Receive Our Newsletter

6 + 1 =

jQuery( document ).ready(function( $ ) { // $( "div" ).hide(); });